2-Natera
Welcome to our virtual exhibit booth! |
|||
|
|
|||
About UsSignatera is a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. |
|||
|
Look deeper at natera.com/oncology |
|||
|
|
|
||
|
|
|
||
|
|
|||
Social Media Links |
|||
